Novo Nordisk launched Ozempic in India on Friday, pricing the 0.25 mg dose at $24.35 per week and targeting a booming diabetes and obesity market expected to power industry growth this decade.

Novo Nordisk launched Ozempic in India on Friday—and the weight-loss drug will sell at a massive discount there, compared with U.S. prices. Novo is selling the 0.25 mg dose at 8,800 rupees ($97.27), ...

Danish Novo Nordisk launched its blockbuster treatment injection Ozempic in three forms in 0.25 mg, 0.5 mg and 1 mg in the 'FlexTouch Pen'.

Ozempic, a GLP-1 receptor agonist, has officially launched in India, offering a new treatment option for type 2 diabetes. While known for its weight l ...

The pre-filled pen, which consists of four doses of 0.25mg injection required for initiation, costs Rs.8800 per month (Rs,2200 per week), 0.5 mg per month costs Rs.10,170 (Rs.2542.5 per week) and 1mg ...

Generally, higher doses of Ozempic are associated with greater weight loss and improved blood glucose control. In a 40-week ...

A medical expert warned of the side effects of the newly launched weight loss drug and advised that the drug should be taken only under strict doctor supervision due to health risks. He also ...

Doctors caution that while Ozempic can help manage diabetes and obesity under medical supervision, misuse as a weight-loss shortcut may lead to nutritional deficiencies, muscle loss, and serious ...

Switching From Tirzepatide to semaglutide for weight loss? This article was reviewed by Lynn Marie Morski, MD, JD. Key takeaways: You can switch from tirzepatide to ...

With this launch, Ozempic now available in India as a once-weekly injectable formulation of semaglutide. It will be available in a pen format in 0.25 mg, 0.5 mg and 1 mg doses in the country.

Ozempic launches in India at just Rs 2,200 for the starting dose. | One of India's leading Digital News Agency offering ...

While both drugs share the same active ingredient, their positioning, pricing, and regulatory pathways diverge sharply, reflecting the company’s effort to capture two massive but different patient ...